Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Accounts Payable
Sonoma Pharmaceuticals Inc
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Accounts Payable
$864k
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-6%
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Payable
$8.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Payable
$3.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Payable
$5.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Payable
$3.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Payable
$2.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
See Also
What is Sonoma Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
864k
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Accounts Payable amounts to 864k USD.
What is Sonoma Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
-6%
Over the last year, the Accounts Payable growth was -34%. The average annual Accounts Payable growth rates for Sonoma Pharmaceuticals Inc have been -29% over the past three years , -5% over the past five years , and -6% over the past ten years .